Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.37 |
| ▸ | F10 | P00742 | 4/20 | 0.33 |
| ▸ | F2 | P00734 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445714 | 0.93 | TAS1R3 (0.39) | TAS1R3TAS1R1F10F2HRH3 | |
| SCHEMBL4248654 | 0.90 | TAS1R3 (0.47) | TAS1R3TAS1R1F10HRH3 | |
| SCHEMBL4255359 | 0.85 | TAS1R3 (0.52) | TAS1R3TAS1R1 | |
| SCHEMBL444241 | 0.83 | TAS1R3 (0.49) | TAS1R3TAS1R1F10HRH3 | |
| SCHEMBL4250157 | 0.83 | TAS1R3 (0.41) | TAS1R3TAS1R1 | |
| SCHEMBL4252461 | 0.80 | TAS1R3 (0.50) | TAS1R3TAS1R1F2 | |
| SCHEMBL445713 | 0.79 | TAS1R3 (0.39) | TAS1R3TAS1R1F10F2HRH3 | |
| SCHEMBL445715 | 0.78 | HRH3 (0.39) | F10F2HRH3 | |
| SCHEMBL4255634 | 0.77 | HPGD (0.45) | F10F2HRH3TPSAB1TPSD1 | |
| SCHEMBL444771 | 0.77 | TAS1R3 (0.56) | TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC8, HDAC3 | TAS1R3 3722/4885TAS1R1 3753/4885F10 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.